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The  dysregulation  of  apoptosis  is  a key  step  in  developing  cancers,  and  mediates  resistance  to  cancer  ther-
apy. Commitment  to  apoptosis  is caused  by permeabilization  of the  outer  mitochondrial  membrane,  a
process  regulated  by the  interactions  between  different  proteins  of  Bcl-2  family.  Furthermore,  Bcl-2 fam-
ily proteins  also bind  to  the  endoplasmic  reticulum,  where  they  modulate  autophagy,  another  important
pathway  regulating  cell  survival  and death.  Dysregulation  of Bcl-2  family  has  been demonstrated  in a
wide  spectrum  of  human  cancers,  including  gastrointestinal  cancers.  Therefore,  targeting  the  Bcl-2 fam-
ily  of proteins  represents  a promising  therapeutic  approach  for  these  malignancies.  Recent  advances
have  yielded  small  molecules  that have close  structural  or functional  similarity  to  BH3-only  proteins
and  are  therefore  named  BH3  mimetics.  Of these  BH3  mimetics,  obatoclax,  (−)-gossypol,  and  ABT-263
are  currently  in  clinical  trials  for multiple  cancers.  Growing  evidence  indicates  that  these  BH3  mimetics
not  only  induce  apoptosis,  but also  regulate  autophagy  which  may  serve  as  a  pro-survival  or  pro-death
mechanism  to counteract  or mediate  the cytotoxicity  of  BH3  mimetics.  This  review  discusses  the  role  of
autophagy  in cell-fate  decision  upon  BH3  mimetics  treatment.  Further  exploration  of our  understanding
of  the association  between  autophagy  and  cellular  outcomes  in response  to  BH3  mimetics  treatment  will
likely  offer  improved  therapies  for patients  with  cancer.. Introduction
The ability of cancer cells to evade apoptosis is a hallmark
f human cancers and a major cause of treatment failure [1,2].
poptosis occurs via activation of two different pathways, the
xtrinsic pathway, triggered by the activation of the cell-surface
eath receptors, and the intrinsic pathway, followed by the per-
urbation of mitochondrial membrane integrity. Structural and
unctional studies have demonstrated that the intrinsic pathway
s tightly controlled by the interactions between the pro- and
nti-apoptotic B-cell lymphoma-2 (Bcl-2) family proteins which
ontrol the integrity of the outer mitochondrial membrane. The
nti-apoptotic Bcl-2 family proteins Mcl-1 and Bcl-xL have been
hown to be among the most commonly ampliﬁed oncogenes in
he cancer genome [3]. Moreover, the anti-apoptotic group of Bcl-2
amily proteins is frequently found to be over-expressed in a wide
ange of cancers including gastrointestinal cancers, causing both
vasion of apoptosis and resistance to treatment [4–7]. As a result,
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© 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY license.targeting the Bcl-2 family of proteins is especially attractive clin-
ically either in single agent therapy or combination treatment in
many cancers [8]. Accordingly, recently identiﬁed small molecules
that have close structural or functional similarity to BH3-only pro-
teins and are therefore named BH3 mimetics, constitute a novel
class of potentially important targeted therapeutics [9].
In addition to inducing apoptosis by directly or indirectly stimu-
lating the mitochondrion-permeabilizing activity of pro-apoptotic
multidomain proteins from the Bcl-2 family as expected, accu-
mulating evidence indicates that BH3 mimetics also regulate
another cellular process, macroautophagy (hereafter referred to as
autophagy). Autophagy, which literally means ‘to eat oneself’, is
an evolutionarily conserved, ubiquitous and multi-step process by
which cytosolic material is sequestered in a double-layered mem-
brane, delivered to the lysosome for degradation and recycled to
sustain cell viability. Autophagy starts with the formation of an
isolation membrane also called phagophore that elongates, encap-
sulates cytoplasmatic cargo and seals to form the autophagosome
[10]. Unlike apoptosis, which is characterized by nuclear conden-
sation and fragmentation without major ultrastructural changes
in cytoplasmic organelles, autophagy is a caspase-independent
© 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY license.process characterized by partial chromatin condensation, cell
membrane blebbing, and the appearance of autophagosomes [11].
For obvious reasons the process is tightly regulated as it operates as
a major homeostatic mechanism to eliminate damaged organelles,
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Fig. 1. According to conserved domain (BH) and its anti or pro-apoptotic action, the54 L. Yu, S. Liu / Seminars in Ca
ong-lived or aberrant proteins and superﬂuous portions of the
ytoplasm. In response to stress signals caused by decreased intra-
ellular metabolite concentrations, autophagy prevents cell death
y replenishing metabolites [12]; however, autophagy can also
ause cell death, depending on the stimuli and environment [13].
This review will focus on gastrointestinal cancers. We  will ini-
ially describe the dysregulation of Bcl-2 family in gastrointestinal
ancers. In the major part of this review, we will discuss how
utophagy is regulated by Bcl-2 family proteins and BH3 mimetics.
e will also concentrate upon the function of autophagy as a cell-
ate decision machinery and explore molecular mechanisms that
ink autophagy to cellular outcome in response to BH3 mimetics
reatment.
. Dysregulation of Bcl-2 family in gastrointestinal cancers
Cancers of the gastrointestinal tract account for more than a
hird of total cancer incidence and nearly half of the cancer-related
eaths in the world [14]. Bcl-2 family dysregulation has been
emonstrated in gastrointestinal cancers (Table 1). The altered
xpression of Bcl-2 family members has been reported in trans-
riptional, translational and post-translational levels. Mutations of
cl-2 family members have also been documented. Notably, some
f these abnormalities have been shown to correlate with clini-
opathological parameters and disease outcomes including overall
urvival in cancer patients [15–37]. These ﬁndings not only under-
core a pivotal role of Bcl-2 family in tumorigenesis, but also
ighlight the possibility of targeting the Bcl-2 family members as a
otential therapeutic avenue for the treatment of gastrointestinal
ancers.
. Bcl-2 family proteins are common players in apoptosis
The mitochondrion serves not only as the cell’s powerhouse,
ut also as a center for integration of signals for apoptosis vs. sur-
ival. Capable of releasing a plethora of pro-apoptotic proteins into
he cytoplasm, mitochondrion is a necessary site of extensive reg-
lation in apoptosis. The Bcl-2 family is an important group of
roteins that was ﬁrst noted to regulate the release of apoptotic
roteins from the mitochondria, speciﬁcally by causing mitochon-
rial outer membrane permeabilization (MOMP). A consequence
f MOMP  is the release of intermembrane space proteins such as
ytochrome c into the cytoplasm, where they allosterically acti-
ate the adaptor protein Apaf-1 to initiate the cascade of caspases
hat cleave substrates leading to cellular apoptosis. Even without
aspase activation, the reduced respiration following cytochrome
 release soon triggers a backup cell death [38]. In this way, the
cl-2 proteins family consists of upstream activators of apoptotic
ignaling in relation to MOMP  [39].
On the basis of various structural and functional characteris-
ics, the Bcl-2 family proteins can be divided into three functional
ubgroups (Fig. 1). Bax, Bak, and the much less studied Bok (Bcl-
-related ovarian killer) represent the multidomain pro-apoptotic
ubgroup of the family and possess three (BH1, BH2, and BH3)
ut of the four evolutionarily conserved -helical Bcl-2 homol-
gy (BH) domains. When exerting their cell-killing activity, Bax
nd Bak damage mitochondria, and either protein sufﬁces for
OMP,  indicative of functional redundancy [40]. A second sub-
et of the family, possessing four BH domains (BH1, BH2, BH3, and
H4), includes ﬁve apoptosis-inhibitory proteins, i.e., the multido-
ain anti-apoptotic proteins Bcl-2, Bcl-xL (B-cell lymphoma-extra
arge), Mcl-1 (myeloid cell leukemia sequence 1), Bcl-w/Bcl2L2
Bcl-2-like protein 2), Bcl2A1 (Bcl-2-related protein A1), and, in
uman only, Bcl-B. Although the ﬁve anti-apoptotic proteins share
xtensive similarity with their multidomain pro-apoptotic rela-
ives, including three-dimensional structure, they protect ratherBcl-2 family can be divided into three subgroups: anti-apoptotic multidomain, pro-
apoptotic multidomain and pro-apoptotic BH3-only. Most family members contain
a  C-terminal hydrophobic transmembrane domain (TM) for membrane anchoring.
than damage mitochondria [41]. Both the pro-apoptotic effectors
and anti-apoptotic Bcl-2 proteins are regulated by a third sub-
group of Bcl-2 proteins, the BH3-only proteins (so named because
of the four BH domains, they contain only BH3). At least eleven
BH3-only proteins have been described in mammals, including
Bcl2-interating mediator of cell death (Bim), BH3-interating-
domain death agonist (Bid), Bcl-2-associated death promoter (Bad),
Bcl2-modifying factor (Bmf), Noxa (the Latin word for damage;
also known as PMAIP1), p53-upregulated modulator of apopto-
sis (Puma), Bcl2-interacting killer (Bik), and Harakiri (Hrk) [42].
The BH3-only proteins function as apoptosis initiators, which bind
and inactivate their pro-survival relatives [43] and perhaps also
transiently bind and activate Bax and Bak [44,45]. The BH3-only
proteins are activated by distinct cytotoxic stimuli in various ways,
including enhanced transcription and post-translational modiﬁca-
tions [46].
The Bcl-2 family can be regarded as a tripartite switch that sets
the threshold for commitment to apoptosis, primarily by inter-
actions within the family [47]. With regard to how the Bcl-2
apoptotic switch is ﬂipped, different models, including ‘direct acti-
vation model’ [44,48], ‘derepression model’ [49,50] and ‘embedded
model’ [51], have been proposed to describe how the interplay
between the three Bcl-2 subgroups activates Bax and Bak and hence
induces MOMP.  The common feature of these models is that the
heterodimetic interactions among different subgroups of the Bcl-
2 family occur through the BH3 ‘ligand’ domain of pro-apoptotic
proteins which bind to a ‘receptor’ BH3-binding groove formed
by BH1-3 regions on the anti-apoptotic proteins. This rational was
successfully employed for the development of new anticancer ther-
apies, in which small molecules acting as BH3-peptide mimetics ﬁt
into the ‘receptor’ binding groove of anti-apoptotic Bcl-2 family
members. Such compounds hold promise for the development of
new anticancer therapies (See below).
4. Autophagy is another cellular process modulated by the
Bcl-2 family
In addition to their anti-apoptotic property, anti-apoptotic
members of Bcl-2 family also function as anti-autophagy pro-
teins via its inhibitory interaction with Beclin 1 [52,53]. Beclin 1,
the mammalian ortholog of yeast Atg6/Vps30, is part of a Class
III PI3K complex that participates in autophagosome formation,
mediating the localization of other autophagy proteins to the pre-
autophagosomal membrane [54]. It was ﬁrst identiﬁed in a yeast
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Table 1
Dysregulation of Bcl-2 family in human gastrointestinal cancers.
Cancer types Nature of dysregulation Clinical correlations References
Colorectal cancer Overexpression of Bcl-2 was observed in 30–94% of cases,
whereas Bcl-2 was weakly expressed in the basal
proliferative layer of normal colonic epithelium
Bcl-2 overexpression is a negative prognostic factor
with respect to recurrence and survival
[15]
Expression of Bcl-xL mRNA in tumor tissues was higher
than that in non-tumor colon tissues
High Bcl-xL expression correlated with poor overall
survival
[16]
Bcl-w was observed in greater than 90% (69/75) of
colorectal adenocarcinomas whereas adenomas
demonstrated a much lower frequency of Bcl-w expression
(1/17)
Increased Bcl-w expression was related to tumor
progression
[17]
Mcl-1 IHC staining was  limited to apical areas in normal
mucosa cells whereas in 50–70% of tumors samples diffuse
expression was  observed
Diffuse IHC staining of Mcl-1 was associated with
poorly differentiated tumors
[18]
Inactivated phosphorylated Bad was  detected in 60.1% of
cases whereas it was not observed in normal colonic
mucosal epithelial cells
ND [19]
Inactivating genetic mutations of Bad gene were detected
in  colon cancer tissues
ND [20]
Frameshift mutations of bax gene were detected in
approximately half of MSI(+) cases
The inactivating mutations of bax were correlated with
poor prognosis
[21]
High Bax expression was  observed in all normal colon
tissue samples whereas it occurred with a lower frequency
(66.4%) in colon cancer tissues
Low Bax expression was correlated with poor overall
survival
[22]
Esophageal cancer Bcl-2 immunoreactivity was higher in poorly
differentiated tumors than well-differentiated tumors
Bcl-2 expression correlated with histopathological
grading and low apoptotic index
[23]
A high expression of Bax was  observed in 67% of cases Low expression of Bax was  correlated with lack of
clinical complete response and poor overall survival
[24]
Bcl-xL was highly positive in dysplasia and tumor cells but
not  in intestinal metaplasia
ND [25]
Gallbladder cancer Overexpression of Bcl-2 was observed in 18.4% of cases. No notable relationship was observed between
apoptosis and overexpression of Bcl-2
[26]
Bax expression in adenocarcinoma was decreased
compared to benign diseased gallbladders
ND [27]
Gastric cancer The expression of Mcl-1 was  higher in gastric cancer
tissues than corresponding noncancerous tissues
High Mcl-1 expression was correlated with poor
5-year overall survival
[28]
Bcl-w was expressed in cancer cells but not in the
neighboring normal mucosa in 46% of cases
Bcl-w expression was associated with the inﬁltrative
morphotypes
[29]
A high expression of Bax was  detected in 31% of cases Low expression of Bax was  associated with poor
survival
[30]
Frameshift Bax mutation was detected in 18.2% of cases Combined p53/Bax mutation was  associated with a
very aggressive clinical course and an extremely poor
prognosis
[31]
Tumor tissues expressed Bcl-2 more frequently compared
with normal tissues
Bcl-2 expression did not correlate with survival [32]
Bcl-xL overexpression was  observed in 63.6% of cases Overexpression of Bcl-xL was  associated with poor
overall survival
[33]
Liver cancer Mcl-1 expression was  enhanced in HCC tissue compared to
adjacent non-tumor tissue
ND [34]
Tumor tissues expressed Bcl-2 more frequently than
tissues of pancreatitis and normal pancreas
ND [35]
A strong positive correlation was  identiﬁed between Bax
expression and p53 expression
Overexpression of Bax was  associated with longer
survival
[36]
Pancreatic cancer Bax mRNA was overexpressed in 61% of cases compared Bax expression was correlated with longer survival [37]
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bbreviations: ND, not determined; MSI, microsatellite instability; ESCC, esophagea
wo-hybrid screen as a Bcl-2-interacting protein [55]. Beclin 1
ossesses a BH3 domain that dictates its interaction with the
H3 receptor domain of anti-apoptotic proteins of the Bcl-2 fam-
ly. Association of Beclin 1 with Bcl-2 family proteins blocks the
utophagy-promoting function of Beclin 1 [56]. It has been reported
hat Beclin 1 directly interacts with Bcl-2, Bcl-xL, Bcl-w and to
 lesser extent with Mcl-1 [57]. Overexpression of Bcl-2 or Bcl-
L has been shown to inhibit autophagy by sequestering Beclin 1
58]. Accordingly, increased expression or stabilization of BH3-only
roteins (such as Bid, Bad or Bik), which bind to anti-apoptotic
roteins through their BH3 domain, reduces the availability of
nti-apoptotic proteins, thereby disinhibiting Beclin 1-dependent
utophagy [56,57,59]. Of note, emerging evidences reveal that the
ompetitive displacement of Beclin 1 by pro-apoptotic proteinsmous cell carcinoma; HCC, hepatocellular carcinoma; IHC, immunohistochemistry.
may  not be of signiﬁcance at all in turning on autophagy, for only the
endoplasmic reticulum (ER)-targeted but not the mitochondrion-
targeted Bcl-2 has been shown to inhibit autophagy [39]. For
instance, studies have shown that Bcl-2 targeted to the ER but
not mitochondrial outer membrane inhibits starvation-induced
autophagy [58]. This suggests that binding of Bcl-2 to Beclin 1 pre-
vents it from assembling the pre-autophagosomal vesicles at an
ER-associated location.
5. The cytotoxicity of BH3 mimetics is modulated by
autophagy
BH3 mimetics are small molecules that have close structural or
functional similarity to BH3-only proteins. Most BH3 mimetics that
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re currently under preclinical and clinical development bind to
nd antagonize anti-apoptotic members of the Bcl-2 family of pro-
eins [60]. Several excellent reviews on the apoptosis-promoting
ffects of these BH3 mimetics have recently been published
51,61–64]. Here, we review the three BH3 mimetics (obatoclax,
−)-gossypol, and ABT-263) that have advanced furthest clinically
n relation to autophagy in a variety of cancers including gastroin-
estinal cancers.
.1. Obatoclax
Obatoclax (GX15-070) is a novel BH3 mimetic pan Bcl-2
nhibitor [65]. In vitro, obatoclax binds to all anti-apoptotic Bcl-
 family members and by ﬂuorescence polarization assays has
C50s in the 1–7 M range for Bcl-2, Bcl-xL, Bcl-w and Mcl-1 [66].
iven the inhibitory effect of anti-apoptotic Bcl-2 family proteins
n Beclin 1, obatoclax is proposed to induce autophagy by disrup-
ing anti-apoptotic Bcl-2 family proteins and Beclin 1 interactions.
onsistent with this idea, obatoclax has been shown to induce inter-
uption of a complex of Mcl-1 and Beclin 1, which contributes to
utophagy induction [67,68]. However, the mechanism by which
batoclax deliberates Beclin 1 from Mcl-1 is unclear. Interestingly,
 recent study demonstrates that obatoclax combined with lap-
atinib increases the protein level of Noxa, which competes away
cl-1 from Beclin 1 leading to autophagy induction [69]. Till now,
here is rare evidence indicating obatoclax liberates Beclin 1 from
ts restraint by direct interacting with anti-apoptotic Bcl-2 family
roteins. Therefore, the mechanism by which obatoclax deliber-
tes Beclin 1 from its Bcl-2 binding partners appears to be more
omplicated than expected. Notably, several studies have shown
hat Beclin 1 independent induction of autophagy by obatoclax, as
nockdown of Beclin 1 failed to blunt obatoclax-induced autophagy
70,71]. In this regard, inhibition of mTOR signaling pathway by
batoclax may  provide an alternative mechanism for autophagy
nduction [67,69].
Although obatoclax has been shown to engage autophagy in
arious cancer cells (Table 2), the critical question whether or not
batoclax-stimulated autophagic activity promotes or inhibits cell
eath has been controversially discussed. On one hand, obatoclax-
nduced autophagy has been linked to cell death, as genetic or
harmacological blockage of autophagy was found to inhibit cell
eath [67,68,70,72–77]. On the other hand, inhibition of autophagy
as demonstrated to enhance obatoclax-induced cell death, sup-
orting a pro-survival function of autophagy [78]. Interestingly,
batoclax-induced autophagy also appears to act as a bystander, as
lockade of autophagy by silencing Atg7 does not impair obatoclax-
riggered cytotoxicity [71].
Besides the above controversial points on the functional rele-
ance of autophagy for obatoclax-induced cytotoxicity, the molec-
lar mechanisms that link autophagy to cell death upon treatment
ith obatoclax is in exploration up till now. In this scenario, subcy-
otoxic dose of obatoclax (100 nM)  combined with dexamethasone
as been shown to activate autophagy-dependent necroptosis,
hich bypassed the block in mitochondrial apoptosis. Execution
f cell death was strictly dependent on expression of receptor-
nteracting protein (RIP-1) kinase, a key regulator of necroptosis
77]. However, it was unclear how RIP-1 was activated and how the
utophagic machinery was connected to the necroptotic pathway.
t is noteworthy that a very recent study seems to have addressed
hese questions. In this study, obatoclax (200 nM)  has been shown
o stimulate assembly of the necrosome on autophagosomal mem-
ranes, which functions as a key event connecting the induction
f autophagy to cell death via necroptosis. Obtoclax promotes the
nteraction of Atg5, a component of autophagosomal membranes,
ith key constituents of the necrosome, that is, FADD, RIP1 and
IP3. This leads to the formation of a cytosolic cell death signalingiology 23P (2013) 553– 560
complex that initiates necroptotic cell death [72]. These ﬁndings
provide new insights into the mechanisms of obatoclax-induced
cell death by linking autophagy induction to necroptosis signaling.
Nevertheless, on contrast to these observations, obatoclax at much
higher concentrations (0.5 and 1 M)  has been demonstrated to
dramatically reduce cell viability and induce autophagy without
inducing loss of plasma membrane integrity, which would not be
the case if necrosis was  being induced [71]. Given RIP1 is critically
required for obatoclax-induced necroptosis, it is tempting to spec-
ulate that the availability and/or function of signaling proteins (e.g.
Atg5, FADD, RIP1) may contribute to determine whether necropto-
sis is engaged for the execution phase.
In contrary to its autophagy-promoting function, obatoclax
has been reported to inhibit the completion of autophagic ﬂux
[69,79]. For instance, obatoclax combined with lapatinib has been
shown to impair autophagic degradation reﬂected by accumula-
tion of undigested large autophagosomes and p62 proteins and
unliquidated damaged mitochondria in breast cancer cells [69].
Given the importance of mitochondrial clearance in the regula-
tion of cell homeostasis, it was  proposed that impaired autophagic
degradation disturbed the proper autophagy ﬂux with pro-survival
function, leading to the accumulation of sequestered but undi-
gested defective mitochondria and precipitating cell death [80].
Consistent with this observation, a recent study shows that oba-
toclax’s anticancer efﬁcacy is associated with an increase in
autophagy initiation without the complete digestion of autophago-
somes in breast cancer cells [79]. Mechanistically, impaired
autophagy ﬂux is due to decreased cathepsin protein expres-
sion with concomitant reduced proteolytic activity. Cathepsins
are lysosomal hydrolases, which are known to degrade autolyso-
somal content [81]. Therefore, obatoclax-induced attenuation of
cathepsin activities limits the ability of cells to use degraded mate-
rial to fuel cellular metabolism and restore homeostasis. Of note,
the concentrations of obatoclax used in the above studies are 50
and 100 nM respectively, which are pharmacologically achievable
and are clinically relevant, as the approximate peak plasma con-
centration of obatoclax is 100 ng/ml (∼250 nM)  [71]. Thus, these
ﬁndings raise the critical question as to whether obatoclax can
impair autophagic degradation not limited to the tested breast
cancer cell lines, if so, whether it can improve the treatment of
cancer when administered in combination with anticancer drugs.
Since adaptive autophagy in cancer cells sustains tumor growth
and survival in face of the toxicity of caner therapy, it is intrigu-
ing to know whether blocking autophagy while giving standard
treatment will improve treatment outcome. It is noteworthy that
some autophagy inhibitors have already been applied in clinical
trails (http://clinicaltrials.gov/ct2/results?term=autophagy). Cur-
rently, autophagy inhibitors hydrooxychloroquine (HCQ) and
chloroquine (CQ) have attracted extensive attention, since they
are clinically used drugs [82]. The toxicological and pharmacoki-
netic proﬁles of these agents are well established and, therefore,
these agents can be easily incorporated into existing regiments
of cancer therapy. In comparison with HCQ and CQ, obatoclax per
se possesses multiple killing mechanisms involving apoptosis and
necroptosis in addition to its autophagy-suppressing activity, it is
tempting to hypothesize that obatoclax may  have more potential
advantages than HCQ and CQ when administered in combination
with anticancer drugs.
Taken together, it appears that obatoclax plays a dual function
in autophagy, in which this reagent exhibits both autophagy-
promoting activity and autophagy-suppressing activity. Data from
recent studies are beginning to unveil the apparently paradox-
ical role of obatoclax in autophagy. In this respect, deliberating
Beclin 1 from anti-apoptotic Bcl-2 family proteins and inhibition
of mTOR signaling pathway by obatoclax in the initial phase of
autophagy may  contribute to its autophagy-promoting function,
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Table 2
Modulation of autophagy in cancer cells by BH3 mimetics.
Cancer cell types Roles in autophagy Fates of autophagy Autophagy inhibitor used References
Obatoclax
Rhabdomyosarcoma cells Induces autophagy Pro-death Baf, Atg5 shRNA, Atg7 siRNA [72]
Colon cancer cells Induces autophagy Pro-death Atg5, Beclin 1 siRNA [73]
ALL Induces autophagy Pro-death Atg5, Beclin 1 siRNA [70]
Leukemia cells Induces autophagy Pro-death CQ [75,76]
Leukemic B cells Induces autophagy Pro-death Beclin 1 siRNA [68]
B-cell lymphoma cells Induces autophagy Pro-death Beclin 1 siRNA [77]
Hepatoma cells Induces autophagy Pro-death Beclin 1 siRNA [74]
Esophageal cancer cells Induces autophagy Pro-survival 3-MA, CQ [78]
Osteosarcoma cancer cells Induces autophagy Pro-survival 3-MA, CQ [78]
Breast cancer cells Inhibits autophagy Pro-survival 3-MA, HCQ, Baf, Beclin 1, Atg7 siRNA [79]
Lung cancer cells Induces autophagy Bystander Beclin 1 shRNA, Beclin 1, Atg7 siRNA [71]
gossypol
Burkitt lymphoma cells Induces autophagy Pro-survival 3-MA [88]
Breast cancer cells Induces autophagy Pro-survival Wort, Vps34, Beclin 1, Atg5 siRNA [85]
Cervical cancer cells Induces autophagy Pro-survival Wort, Vps34, Beclin 1, Atg5 siRNA [85]
Prostate cancer cells Induces autophagy Pro-death 3-MA, Beclin 1, Atg5 siRNA [86,87]
Glioma cells Induces autophagy Pro-death Baf, Beclin 1, Atg5 siRNA [90]
ABT-737
Lung cancer cells Induces autophagy Uncertain 3-MA, CQ, Beclin 1 shRNA [102]
Lymphocytic leukemia cells Induces autophagy Uncertain 3-MA, CQ [101]
Cervical cancer cells Induces autophagy Bystander ND [98]
Colon cancer cells Induces autophagy Bystander ND [98]
Prostate cancer cells Induces autophagy Pro-survival HCQ, Beclin 1 siRNA [99]
Melanoma cells Induces autophagy Pro-survival Atg7 siRNA [100]
Abbreviations: ALL, acute lymphoblastic leukemia; Baf, baﬁlomycin A1; BH3, Bcl-2 homology domain 3; CQ, chloroquine; HCQ, hydoxychloroquine; ND, not determined;
Wort,  wortmannin; siRNA, small interfering RNA, shRNA, short hairpin RNA; 3-MA, 3-methyladenine.
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utophagy. As a pro-survival or pro-death mechanism, blockade of autophagy enhan
o  the situation that blockade of autophagy does not affect the inhibitory effect.
hereas attenuation of cathepsin activities by obatoclax in the ﬁnal
tep of autophagy may  contribute to its autophagy-suppressing
unction. However, the molecular mechanisms those determine
hether obatoclax promotes autophagy or inhibits autophagy have
emained obscure. Further investigations are needed to achieve
echanistic insights on this issue.
.2. Gossypol
Gossypol is a natural polyphenolic compound derived from
ottonseeds, which has been identiﬁed as a small molecule pan-
nhibitor of anti-apoptotic Bcl-2 family members including Bcl-2,
cl-xL, and Mcl-1, and Bcl-w [83,84]. Natural gossypol is a racemic
ixture of (+)-gossypol and (−)-gossypol, the latter being more
otent as an inhibitor of tumor growth. Accordingly, (−)-gossypol is
he most clinically acceptable form of gossypol and has been brand
amed as AT-101 (Ascenta) [64].
Gossypol and (−)-gossypol have been reported to induce
utophagy in various cancer cells (Table 2). Functioning as a pan-
cl-2 inhibitor, gossypol inhibits the interaction between Beclin 1
nd Bcl-2, antagonizes the inhibition of autophagy by Bcl-2, and
ence stimulates autophagy [85–87]. Interestingly, (−)-gossypol is
lso able to induce Beclin 1-dependent autophagy by additional
echanisms. For instance, (−)-gossypol has been shown to increase
OS generation, subsequently leading to cytosolic translocation of
igh mobility group box 1 (HMGB1) [88]. HMGB1 directly inter-
cts with Beclin 1, displacing Bcl-2, and thereby induces autophagy
89]. Furthermore, (−)-gossypol has been shown to downregu-
ate expression of Mcl-1 and Bcl-2, which possibly leads to less
nti-apoptotic Bcl-2 proteins available for sequestering Beclin 1
nd therefore induces autophagy [86,87,90]. Of note, gossypol also
nduces Beclin 1-independent autophagy, which may  result from
ts inhibitory action on mTOR signaling pathway [85].
Consistent with the dual functions of autophagy in cell-fate deci-
ion, both pro-survival and pro-death effects have been implicatedrmacological inhibitors or RNA interference targeting genes that are essential to
 attenuates the inhibitory effect of the BH3 mimetic, respectively. ‘Bystander’ refers
in gossypol-induced autophagy (Table 2). The accumulative evi-
dence indicates that the pro-survival function of autophagy has
been linked to its ability to suppress various forms of cell death,
including apoptosis [91–94]. In support of this idea, gossypol
and (−)-gossypol have been observed to induce cytoprotective
autophagy, for suppression of autophagy using either pharmaco-
logical inhibitors or RNA interference with essential autophagy
genes enhances apoptosis induced by these compounds [85,88].
In contrast, several studies also demonstrate that (−)-gossypol
induces autophagic cell death in prostate cancer cells and glioma
cells [86,87,90].
It is interesting to note that (−)-gossypol induced pro-survival
autophagy in MCF-7 and Hela cells, whereas triggered autophagic
cellular death in glioma cells with similar dosage and identi-
cal treatment time [85,90]. Moreover, mitochondrial dysfunction
featured with mitochondrial fragmentation, swelling, or loss of
cristae has been observed in both cells occurring self-defensive
autophagy and cells occurring self-destructive autophagy in these
studies [85,90]. These ﬁndings raise the question about the critical
determinants for cells to be driven toward autophagy with differ-
ent functions in response to (−)-gossypol treatment. Considering
the important role of mitochondria in controlling the fate of cell,
it appears reasonable to speculate that upon (−)-gossypol treat-
ment, self-defensive autophagy occurs to ensure the turnover of
damaged mitochondria. However, if increased mitochondrial dam-
age reaches a “threshold” level above which excessive autophagy
occurs and is followed by cell death. Therefore, the degree of mito-
chondrial damage and the capability of cells to deal with damaged
mitochondria appear to contribute to determine which type of
autophagy will occur upon gossypol treatment.5.3. ABT-737 and ABT-263
Of the Bcl-2 inhibitors discovered to date, one of the most
promising candidates that selectively kills cancer cells through
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irect interaction with the Bcl-2 family is the BH3 mimetic ABT-
37. It selectively binds to and inhibits Bcl-2, Bcl-xL and Bcl-w with
anomolar afﬁnities, while it binds with poor afﬁnity to Mcl-1 and
ﬂ-1 with a dissociation constant in the micro-molar range [95].
BT-263 (navitoclax) is the orally applicable version of ABT-737,
hich has a similar binding proﬁle and afﬁnities to anti-apoptotic
cl-2 family proteins as ABT-737 [64]. Till now, there is rare study
nvestigating the association between ABT-263 and autophagy.
herefore, we focus on ABT-737 in relation to autophagy.
ABT-737 has been shown to competitively disrupt the inhibitory
nteraction between Beclin 1 and Bcl-2 or Bcl-xL, thus allowing
eclin 1 to accomplish its autophagic stimulatory functions [96,97].
otably, a recent study measures the possible effects of ABT-737
n multiple distinct autophagy regulators beyond that organized by
eclin 1. According to this study, ABT-737 causes the activation of
MPK, the inhibition of mTOR, dephosphorylates p53, and deac-
ivates the autophagy-inhibitory Akt kinase. These results point
o unexpected and pleiotroic pro-autophagic effects of ABT-737
nvolving the modulation of multiple signaling pathways [98].
With regard to the function of ABT-737-induced autophagy in
elation to cell-fate decision (Table 2), it has been shown that
nduction of autophagy by ABT-737 was a mechanism of resis-
ance in prostate cancer cells. Therapeutic inhibition of autophagy
ith HCQ increased cytotocixity of ABT-737 both in vitro and
n vivo [99]. Similarly, ABT-737 promoted autophagy and hence
ell survival in melanoma cells, as abrogation autophagy by Atg7
nockdown resulted in a signiﬁcant increase in cell death [100].
nterestingly, autophagy induced by ABT-737 also appears to act
s a bystander, whose induction does not interfere with cell death
98]. However, in some scenarios, the role of autophagy in cell-fate
ecision is uncertain whose inhibition by different inhibitors yields
ontroversial results. For instance, the cytotoxicity of ABT-737 in
ombination with vesicular stomatitis virus (VSV) was partially
eversed by CQ, however, inhibition of autophagy with 3-MA led to
ncreased apoptosis [101]. Similar to this study, ABT-737 has been
hown to induce cytoprotective autophagy, since two inhibitors of
utophagy (CQ and 3-MA) augmented cytototoxic action of ABT-
37. Surprisingly, and in sharp contrast to the results obtained with
he pharmacological inhibitors, knockdown of Beclin 1 diminished
BT-737-induced cytotoxicity, indicating that cellular destructive
ather than cytoprotective autophagy occurred [102]. Several pos-
ible explanations are proposed for these seemingly contradictory
esults. First, pharmacological inhibitors of autophagy used could
ave biological effects on the regulation of cell survival indepen-
ent of the autophagy pathway. Second, Beclin 1 and Bcl-2 are
nown to directly interact, and knockdown of Beclin 1 may  affect
cl-2 function or localization independent of any effect on induc-
ion of autophagy. Discussing the advantages and pitfalls of these
utophagy inhibitors is beyond the scope of this article. Neverthe-
ess, it may  be advisable to interrogate possible cases of autophagic
ell death or cytoprotective autophagy by knocking down at least
wo distinct essential autophagic proteins in addition to pharma-
ological inhibitors.
. Conclusions and future perspectives
Much progress has been made in the last few years on the
echanisms by which the Bcl-2 family proteins function through
elective interactions to control mitochondrial apoptosis. Recently,
mall molecules capable of inhibiting the interactions of the anti-
poptotic Bcl-2 protein family have been developed and three BH3
imetics, obatoclax, (−)-gossypol and ABT-263, have progressed
nto clinical studies. Apart from their pro-apoptotic property,
ccumulating evidence indicates that BH3 memetics, including
batoclax, (−)-gossypol and ABT-737, also regulate autophagyiology 23P (2013) 553– 560
both in Beclin 1-dependent and Beclin 1-independent pathways.
There has been no publication regarding the association between
autophagy and ABT-263 during preparation of this review. Further
investigations are needed on this issue.
In cancer therapy, autophagy is induced in cancer cells as an
adaptive response to promote cell survival. However, in certain
circumstances, autophagy is required for the cytotoxic action of
some anticancer agents [103]. In line with this concept, BH3  mimet-
ics have been shown to induce both self-defensive autophagy and
self-destructive autophagy in various cancer cells. In the case that
autophagy contributes to survival, pharmacological blockage of
autophagy by clinically available autophagy inhibitors such as HCQ
and CQ has been shown to enhance BH3 mimetics-induced cell
death [78,99]. Of note, in addition to its autophagy-promoting
function, obatoclax has been reported to inhibit the completion of
autophagic ﬂux, leading to the accumulation of sequestered but
undigested defective mitochondria and precipitating cell death.
Whether ABT compounds and (−)-gossypol also exert similar
autophagy-inhibitory action is unclear. In the case that autophagy
contributes to both death and survival, it is important to deter-
mine if the pro-death or pro-survival action of autophagy is induced
upon a BH3 mimetic treatment. Equally important, is the molecu-
lar mechanism governing cell-fate decision during autophagy upon
BH3 mimetics treatment. Such knowledge will likely foster the
future development of strategies in relation to autophagy to better
direct the use of these BH3 mimetics in the clinic.
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